Sadleir P H M, Russell T, Clarke R C, Maycock E, Platt P R
Department of Anaesthesia, Sir Charles Gairdner Hospital, Western Australia, Australia.
Anaesth Intensive Care. 2014 Jan;42(1):93-6. doi: 10.1177/0310057X1404200116.
Sugammadex is a selective binding agent for aminosteroid neuromuscular blockers whose use is increasing in anaesthetic practice. We present three cases of severe anaphylaxis coincident with sugammadex administration. Subsequent intradermal testing confirmed sugammadex as the triggering agent, with all patients having positive skin responses to a 1:100 dilution of the standard 100 mg/ml solution and two out of three having a positive response to a 1:1000 dilution. As all patients were administered sugammadex to reverse neuromuscular blockade with rocuronium, we considered that sugammadex-rocuronium complexes were a potential unique allergen. In the two patients who were additionally tested with a rocuronium-sugammadex (3.6:1 molecular ratio) mixture, the wheal-and-flare response was significantly attenuated.
舒更葡糖钠是一种用于氨基甾体类神经肌肉阻滞剂的选择性结合剂,其在麻醉实践中的应用正在增加。我们报告了3例与舒更葡糖钠给药同时发生严重过敏反应的病例。随后的皮内试验证实舒更葡糖钠为触发剂,所有患者对标准100mg/ml溶液1:100稀释液的皮肤反应均为阳性,三分之二的患者对1:1000稀释液有阳性反应。由于所有患者均接受舒更葡糖钠以逆转罗库溴铵的神经肌肉阻滞作用,我们认为舒更葡糖钠-罗库溴铵复合物是一种潜在的独特变应原。在另外两名用罗库溴铵-舒更葡糖钠(分子比3.6:1)混合物进行测试的患者中,风团及潮红反应明显减弱。